目录产品 » CD155/PVR, His, Rhesus macaque

CD155/PVR, His, Rhesus macaque

CD155 is a cell surface adhesion molecule functioning in tumor cell migration, invasion, and metastasis, and not surprisingly, is also designated as a common tumor-associated antigen. CD155 is also recognized by NK cells to induce their cytotoxicity. CD155 is also commonly referred to as the "poliovirus receptor," or PVR.
Z04355
¥3500

联系我们
Species Rhesus macaque
Protein Construction
CD155/PVR (Asp28-Asn343)
Accession # Q0MSE6-1
His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized CD155/PVR, His, Rhesus macaque at 2μg/ml (100μl/well) on the plate can bind Human TIGIT, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 35.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 46-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Target Background CD155 is a cell surface adhesion molecule functioning in tumor cell migration, invasion, and metastasis, and not surprisingly, is also designated as a common tumor-associated antigen. CD155 is also recognized by NK cells to induce their cytotoxicity. CD155 is also commonly referred to as the 'poliovirus receptor,' or PVR.
Synonyms CD155; HVED; NECL5; Necl-5; nectin-like 5; PVR; PVS; Tage4; PVSFLJ25946; FLJ25946

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.


喜欢新升级的网站吗?

讨厌

不喜欢

一般

喜欢

非常喜欢

*